Explore the positions available across Oxford Science Enterprises

T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio believes that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of such therapies. T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.